Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Relapsing-remitting

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    297 result(s) found for: Relapsing-remitting. Displaying page 8 of 15.
    EudraCT Number: 2017-000426-35 Sponsor Protocol Number: 1.0 Start Date*: 2018-04-17
    Sponsor Name:Medical University of Vienna - Department of Neurology
    Full Title: Efficacy of Rituximab at low doses in Multiple Sclerosis – A prospective, randomized, double-blind, active controlled, pilo trial
    Medical condition: Relapse Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005003-24 Sponsor Protocol Number: 109MS202 Start Date*: 2015-06-01
    Sponsor Name:Biogen Idec Research Limited
    Full Title: Open-Label, Multicenter, Multiple-Dose Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis Aged 10 to 17 Years
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    17.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LV (Completed) DE (Completed) CZ (Completed) BG (Completed) PL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017490-38 Sponsor Protocol Number: 101MS205 Start Date*: 2010-05-03
    Sponsor Name:Biogen Idec
    Full Title: Randomized Treatment Interruption of Natalizumab
    Medical condition: Natalizumab is a highly efficacious therapy used in the treatment of patients with relapsing multiple sclerosis (MS). This is a prospective randomized study in subjects with relapsing forms of MS w...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-005746-15 Sponsor Protocol Number: MN43964 Start Date*: 2022-08-05
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Multicenter, Single-arm, Open-label, Extension, Rollover Study To Evaluate The Long-term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis
    Medical condition: Primary Progressive Multiple Sclerosis (PPMS) Relapsing Multiple Sclerosis (RMS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Trial now transitioned) SE (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned) LT (Trial now transitioned) NO (Completed) SK (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) LV (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) PT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) HR (Trial now transitioned) FR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004562-22 Sponsor Protocol Number: 109MS416 Start Date*: 2015-06-10
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients with M...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    17.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) CZ (Completed) HU (Prematurely Ended) IT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003930-16 Sponsor Protocol Number: SIMCOMBIN Start Date*: 2006-01-19
    Sponsor Name:Biogen Idec A/S
    Full Title: A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Mu...
    Medical condition: Patients with definite relapsing-remitting multiple sclerosis who have never received treatment with interferons or glatiramer acetate, who meet all the criteria for inclusion and none of the exclu...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10028425 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-001362-25 Sponsor Protocol Number: RAM-MS Start Date*: 2018-05-02
    Sponsor Name:Helse Bergen HF, Haukeland University Hospital
    Full Title: Randomized autologous hematopoietic stem cell transplantation versus alemtuzumab, cladribine or ocrelizumab for patients with relapsing remitting Multiple Sclerosis
    Medical condition: Relapsing remitting multiple sclerosis.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001895-40 Sponsor Protocol Number: 109MS406 Start Date*: 2014-05-02
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Phase 4, Randomized, Double-Blind Study with a Safety Extension Period to Evaluate the Effect of Aspirin on Flushing Events in Subjects with Relapsing-Remitting Multiple Sclerosis Treated with Te...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    16.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014724-32 Sponsor Protocol Number: SABA Start Date*: Information not available in EudraCT
    Sponsor Name:University Medical Center Eppendorf
    Full Title: SAFETY, TOLERABILITY AND MECHANISM OF ACTION OF BOSWELLIC ACIDS (BA) IN MULTIPLE SCLEROSIS (MS) AND CLINICALLY ISOLATED SYNDROME (CIS): A MRI-CONTROLLED, MULTICENTER, BASELINE-TO-TREATMENT, 32-WEEK...
    Medical condition: Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001253-13 Sponsor Protocol Number: ROCHIMS Start Date*: 2017-08-23
    Sponsor Name:UZ Brussel
    Full Title: Does cerebral hypoperfusion play a role in reduced axonal metabolism and clinical disability in patients with multiple sclerosis ?
    Medical condition: Patients suffering relapsing- remitting multiple sclerosis will be investigated in this study, with an EDSS score less or equal to 4.0. Patients must be older than 18 years old. There must not be a...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002566-13 Sponsor Protocol Number: NEXT-MS Start Date*: 2019-12-19
    Sponsor Name:Amsterdam University Medical Center
    Full Title: Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis
    Medical condition: Relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10070425 Multiple sclerosis exacerbation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000516-22 Sponsor Protocol Number: 800MS301 Start Date*: 2019-07-08
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3- Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 ...
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PT (Not Authorised) EE (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000922-12 Sponsor Protocol Number: TV44400-CNS-40083 Start Date*: 2016-01-04
    Sponsor Name:Teva Pharmaceutical Industries, Ltd
    Full Title: A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Treated with Subcutaneous...
    Medical condition: Relapsing-Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Completed) IE (Completed) PL (Completed) FI (Completed) ES (Completed) HR (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-005148-28 Sponsor Protocol Number: 25643 Start Date*: 2005-05-26
    Sponsor Name:Merck Serono International S.A.
    Full Title: A phase III, randomised, double-blind, three-arm, placebo-controlled, multi-center study to evaluate the safety and efficacy of oral Cladribine in subjects with relapsing remitting multiple sclerosis
    Medical condition: Relapsing-remitting multiple sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    7.0 10028245 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) DK (Completed) EE (Completed) CZ (Completed) BE (Completed) IT (Completed) AT (Completed) SK (Completed) LT (Completed) DE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2018-002648-10 Sponsor Protocol Number: 7109 Start Date*: 2019-04-15
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: TestOsterone TreatmEnt on neuroprotection and Myelin repair in Relapsing Remitting Multiple Sclerosis
    Medical condition: Relapsing Remitting Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000150-31 Sponsor Protocol Number: ET.ST.02/10MP Start Date*: 2011-04-13
    Sponsor Name:FONDAZIONE DON CARLO GNOCCHI ONLUS
    Full Title: EFFECTS OF GLATIRAMER ACETATE ON TISSUE DAMAGE, CORTICAL FUNCTIONS AND FATIGUE IN MULTIPLE SCLEROSIS: A MORPHO-FUNCTIONAL MRI STUDY.
    Medical condition: Multiple Sclerosis patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10012303 Demyelinating disorders HLGT
    14.1 10029205 - Nervous system disorders 10052785 Multiple sclerosis acute and progressive HLT
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    14.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001224-22 Sponsor Protocol Number: 215MS202 Start Date*: 2017-12-28
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as ...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10067063 Progressive relapsing multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) CZ (Completed) HU (Prematurely Ended) BE (Completed) NL (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005989-37 Sponsor Protocol Number: 308841 Start Date*: 2006-03-29
    Sponsor Name:Schering Oy
    Full Title: CogniMS: observational study to assess cognition in patients with early Multiple Sclerosis
    Medical condition: Observational Study to assess cognition in patients with early Multiple Sclerosis. Relapsing-Remitting MS-patients diagnosed within 2 years and who have started the Betaferon treatment (interferon-...
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004533-32 Sponsor Protocol Number: 109MS305 Start Date*: 2014-04-28
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of BG00012 in Subjects From the Asia Pacific Region and Other Countries With Relapsing-Remitting Multiple Scle...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-003484-30 Sponsor Protocol Number: CFTY720DES03 Start Date*: 2011-10-26
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A multi-centre, open-label, non-randomised, parallel group clinical trial to assess the efficacy of fingolimod in naïve patients versus fingolimod in patients previously treated with interferons or...
    Medical condition: Multiple Sclerosis relapsing-remitting course
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 11 04:51:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA